www.msn.com

www.msn.com
Share

www.msn.com

 •  October 9

In a blow to the pharmaceutical industry, California Gov. Jerry Brown is expected on Monday to sign a bill that would require drug makers to explain and justify price hikes, making this the latest state to actively address the high cost of medicines. The bill, which has been vociferously fought by the pharmaceutical industry, is set to become one...

www.msn.com

 •  October 9

(Bloomberg) -- A California law to make drug companies explain price increases will also extend a state-by-state battle between lawmakers trying to bring more transparency to the industry’s practices and drugmakers that oppose the efforts. The California measure, signed Monday by Governor Jerry Brown, is among the most aggressive state efforts to...

www.msn.com

 •  September 28

In a blow to Alexion Pharmaceuticals (ALXN), a Canadian government agency ordered the drug maker to lower the price of a rare disease medicine and reimburse the government for “excessive” pricing. The ruling by the Patented Medicine Prices Review Board follows a long-running struggle that began after the drug maker three years ago refused to lower...

www.msn.com

 •  September 26

(Bloomberg) -- Alvogen’s private equity owners including CVC Capital Partners are exploring options for the generic pharmaceutical company, which could be valued at about $4 billion, according to people familiar with the matter. The controlling shareholders of the drugmaker have held on-and-off talks with Shanghai Pharmaceuticals Holding Co....

www.msn.com

 •  September 25

The Food and Drug Administration has responded to charges filed against Aegerion Pharmaceuticals, Inc., of violating the Federal Food, Drug and Cosmetic Act. On Friday, Aegerion Pharmaceuticals agreed to plead guilty in U.S. District Court to two misdemeanor counts of violating the FD&C Act. They did so for the introduction of a misbranded drug...

www.msn.com

 •  September 20

Attorney General Maura Healey, along with attorneys general from 38 other states, is seeking information from five opioid manufacturers and three distributors as they expand an investigation into the origins of the addiction crisis that has claimed thousands of lives. At an announcement Tuesday in Boston, Healey said the attorneys general are...

www.msn.com

 •  September 15

Good morning and happy Friday, readers! This is Sy. The Food and Drug Administration (FDA) continued its potentially record-breaking pace of new drug approvals Thursday, green lighting the first-ever “biosimilar” copycat of a cancer drug. The new treatment, U.S. biotech Amgen’s Mvasi, has a big target in its crosshairs: Avastin, a versatile cancer...

www.msn.com

 •  September 14

THURSDAY, Sept. 14, 2017 (HealthDay News) -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of adults with certain colon, lung, brain, kidney and cervical cancers. A biosimilar is...

www.msn.com

 •  September 6

ProQR Therapeutics N.V. PRQR announced that its pipeline candidate, QRX-421, has received orphan drug designation (ODD) from the FDA and European Medicines Agency (“EMA”) for Usher syndrome. In fact, QRX-421 is the third candidate in the company’s ophthalmology pipeline and the fourth drug in the broader pipeline to receive ODD from the FDA and...

www.msn.com

 •  September 1

The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML). The drug was cleared to treat adults with newly diagnosed AML whose tumors express the CD33 antigen, as well as patients aged 2 years and older with CD33-positive AML who have relapsed, or did respond...